WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex
Pharmaceuticals, Inc., a clinical stage biopharmaceutical company
developing proprietary pharmaceuticals for the treatment of
inflammatory lung diseases and cancer, today announced that
Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex's DSTAT
investigational product, yesterday reported promising results
of the first cohort of patients hospitalized with
COVID-19-associated Acute Lung Injury (ALI), suggesting that
dociparstat sodium (DSTAT) may accelerate recovery from ALI, as
well as mitigate thrombotic events in such patients. A copy of
Chimerix' press release and detailed information can be found
at https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-promising-topline-results-first-cohort
Stephen G. Marcus, M.D., CEO of
Cantex, commented: "We are very pleased that our ongoing
collaboration under our license agreement with Chimerix has led to
early promising results in the important setting of the treatment
of hospitalized patients with COVID-19 infection. In the
context of the Joint Development Committee established at the time
of the license agreement, Cantex will continue to support the
development of DSTAT for ALI, acute myeloid leukemia (AML), and
other important indications."
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical
company focused on developing novel treatments for inflammatory
lung diseases and cancer.
Cantex's pipeline consists of two product candidates –
Dicopp® and DSTAT. Both drugs are in clinical
development for diseases where innovative and more effective
treatments are urgently needed.
Dicopp®, which is an orally-administered proprietary
combination of disulfiram + copper, is being developed for the
treatment of long-term complications of COVID-19 infection. A Phase
2 clinical study of Dicopp® as a treatment of the
prolonged disabling complications of COVID-19 infection commonly
known as "Long Haul COVID-19", is expected to begin in 2021. A
separate Phase 2 clinical study of Dicopp® in
relapsed/refractory myeloma is expected to begin in early 2021.
DSTAT, licensed to Chimerix in July
2019, is currently being studied in two disease indications,
COVID-19-associated ALI and AML, and has other potential
indications. Cantex remains involved in the continued development
of DSTAT via a Joint Development Committee with Chimerix. In
COVID-19-associated ALI, DSTAT is currently the subject of an
ongoing Phase 2/3 clinical trial. Chimerix recently opened
clinical trial sites and is ready to begin screening patients for
its 570-subject Phase 3 Dociparstat in AML
with Standard Chemotherapy (DASH AML) study of
DSTAT for the treatment of AML.
For more information, please
visit www.cantex.com.
CONTACT:
Stephen
Marcus, M.D.
CEO
Cantex Pharmaceuticals, Inc.
Tel: 954-315-3660
View original
content:http://www.prnewswire.com/news-releases/chimerix-exclusive-worldwide-licensee-of-cantexs-investigational-product-dstat-has-announced-promising-topline-results-from-the-first-cohort-of-a-randomized-covid-19-clinical-trial-301236633.html
SOURCE Cantex Pharmaceuticals, Inc.